Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. | *11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf Gilteritinib (Xospata) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf Gilteritinib (Xospata) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' ASP2215 | *'''Code name:''' ASP2215 | ||
*'''Brand name:''' Xospata | *'''Brand name:''' Xospata | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 11:10, 4 April 2021
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Patient Drug Information
Also known as
- Code name: ASP2215
- Brand name: Xospata